R&D cost reflected to medical insurance drug prices

In the top executive meeting of the KPMA it was agreed that the R&D cost for a new drug development should be reflected to the medical drug insurance price so that the company could return their heavy investment as early as possible.

The early investment return even for a modified new product should be recognized and accepted if the product is deemed it innovative and economic so that the do...